True, but BP has always understood and believed in leronlimab and the CCR5 MOA. I’d imagine he received CYDY shares for advisory or lab services before the 13D activity. If he later sold those shares, it was probably either an emotional decision or based on a belief the company was heading toward bankruptcy.

I stopped following the company closely after the 13D and NP saga, so I may be in the minority of current shareholders. That said, I welcome BP advising the FDA on long COVID, given his knowledge and expertise in this space—it could lead to better treatment options for patients and potentially renewed support for leronlimab. I’d honestly be surprised if he threw his full support behind alternatives like maraviroc, considering its safety profile, even though it’s already approved and readily available.